Table 2.
The association between clinicopathological features and SII-PNI score
Characteristics | SII-PNI | P | ||
---|---|---|---|---|
0 score (N = 107) |
1 score (N = 41) |
2 score (N = 33) |
||
Gender | 0.959 | |||
Male | 79(73.83%) | 31(75.61%) | 24(72.73%) | |
Female | 28(26.17%) | 10(24.39%) | 9(27.27%) | |
Age (years) | 0.057 | |||
≤ 60.0 | 62(57.94%) | 18(43.90%) | 12(36.36%) | |
>60.0 | 45(42.06%) | 23(56.10%) | 21(63.64%) | |
ECOG performance status | 0.765# | |||
0 | 96(89.72%) | 37(90.24%) | 31(93.94%) | |
1 | 11(10.28%) | 4(9.76%) | 2(6.06%) | |
Tumor size (cm) | 0.315 | |||
< 5.0 | 30(28.04%) | 16(39.02%) | 8(24.24%) | |
≥ 5.0 | 77(71.96%) | 25(60.98%) | 25(75.76%) | |
Lesion site | 0.239# | |||
Up 1/3 | 46(42.99%) | 20(48.78%) | 10(30.30%) | |
Middle 1/3 | 12(11.21%) | 8(19.51%) | 5(15.15%) | |
Low 1/3 | 49(45.79%) | 13(31.71%) | 18(54.55%) | |
Differentiation | 0.002 | |||
Poor | 55(51.40%) | 31(75.61%) | 26(78.79%) | |
Moderately or well | 52(48.60%) | 10(24.39%) | 7(21.21%) | |
cTNM stage | 0.079 | |||
II | 32(29.91%) | 16(39.02%) | 5(15.15%) | |
III | 75(70.09%) | 25(60.98%) | 28(84.85%) | |
Chemotherapy regimen | 0.891 | |||
XELOX | 54(50.47%) | 22(53.66%) | 18(54.55%) | |
SOX | 53(49.53%) | 19(46.34%) | 15(45.45%) |
Note # Fisher’s exact test